Suppr超能文献

青黛汤可抑制致死期前列腺癌模型中前列腺癌的生长。

Qingdai Decoction suppresses prostate cancer growth in lethal-stage prostate cancer models.

作者信息

Chen Yanhua, Zhou Qianqian, Zhang Hong, Xu Linfan, Lu Lianheng, Shu Bing, Zhou Lihong, Yuan Fuwen

机构信息

Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.

Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 Wan-Ping South Road, Shanghai, 200032, China.

出版信息

J Ethnopharmacol. 2023 May 23;308:116333. doi: 10.1016/j.jep.2023.116333. Epub 2023 Feb 28.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Contemporary therapy for advanced castration-resistant prostate cancer (CRPC) employs reagents such as enzalutamide and abiraterone acetate targeting the androgen receptor (AR) transcription axis only provide a temporary response and rapidly develop resistance. Additionally, neuroendocrine prostate cancer (NEPC) is an AR pathway-independent and lethal-stage prostate cancer with no standard therapy. Qingdai Decoction (QDT), a traditional Chinese medicine formula, has various pharmacological activities and was widely used for the treatment of different diseases including prostatitis which may contribute to prostate cancer development.

AIM OF THE STUDY

This study aims to explore the anti-tumor role and potential mechanism of QDT on prostate cancer.

MATERIAL AND METHODS

CRPC prostate cancer cell models and xenograft mice models were established for research. The effect of TCMs on cancer growth and metastasis were determined by CCK-8, wound-healing assays and the PC3-xenografted mice model. The toxicity of QDT in the major organs was investigated by H&E staining. The compound-target network was analyzed with network pharmacology. The correlation of QDT targets with prostate cancer patient's prognosis was analyzed with multiple prostate cancer patient cohorts. The expression of related proteins and mRNA were detected by western blot and real-time PCR. The gene knockdown was achieved with CRISPR-Cas13 technology.

RESULTS

By integrating functional screening, network pharmacology analysis, CRISPR-Cas13 directed RNA targeting, and molecular biology validation in different prostate cancer models and clinical prostate cancer cohorts, we found that Qingdai Decoction (QDT), a Traditional Chinese Medicine, can repress cancer growth in advanced prostate cancer models in vitro and in vivo in an AR independent manner by targeting NOS3, TGFB1, and NCOA2.

CONCLUSION

This study not only identified QDT as a novel drug for lethal-stage prostate cancer treatment but also provided an extensive Integrative research paradigm for investigating the roles and mechanisms of TCMs for the treatment of other diseases.

摘要

民族药理学相关性

晚期去势抵抗性前列腺癌(CRPC)的当代治疗方法使用恩杂鲁胺和醋酸阿比特龙等试剂,这些试剂仅靶向雄激素受体(AR)转录轴,只能提供暂时的缓解,并且很快就会产生耐药性。此外,神经内分泌前列腺癌(NEPC)是一种不依赖AR途径的致命阶段前列腺癌,目前尚无标准治疗方法。青黛汤(QDT)是一种中药配方,具有多种药理活性,广泛用于治疗包括前列腺炎在内的不同疾病,而前列腺炎可能促进前列腺癌的发展。

研究目的

本研究旨在探讨青黛汤对前列腺癌的抗肿瘤作用及其潜在机制。

材料与方法

建立CRPC前列腺癌细胞模型和异种移植小鼠模型用于研究。通过CCK-8、伤口愈合试验和PC3异种移植小鼠模型确定中药对癌症生长和转移的影响。通过苏木精-伊红(H&E)染色研究青黛汤对主要器官的毒性。用网络药理学分析化合物-靶点网络。用多个前列腺癌患者队列分析青黛汤靶点与前列腺癌患者预后的相关性。通过蛋白质免疫印迹法和实时聚合酶链反应检测相关蛋白和mRNA的表达。使用CRISPR-Cas13技术实现基因敲低。

结果

通过在不同前列腺癌模型和临床前列腺癌队列中整合功能筛选、网络药理学分析、CRISPR-Cas13导向的RNA靶向和分子生物学验证,我们发现中药青黛汤(QDT)可以通过靶向一氧化氮合酶3(NOS3)、转化生长因子β1(TGFB1)和核受体辅激活因子2(NCOA2),以AR非依赖性方式抑制晚期前列腺癌模型在体外和体内的癌症生长。

结论

本研究不仅确定青黛汤为治疗致命阶段前列腺癌的新药,还为研究中药治疗其他疾病的作用和机制提供了一个广泛的综合研究范例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验